FDA is announcing today it has placed Elevidys and certain Sarepta investigational gene therapy clinical trials for limb girdle muscular dystrophy on clinical hold due to new safety concerns that the study participants are or would be exposed to an unreasonable and significant risk of illness or in
Source: FDA Press Releases